|Bid||44.90 x 100|
|Ask||46.00 x 100|
|Day's Range||48.25 - 49.44|
|52 Week Range||19.91 - 63.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.82|
MADISON, Wis., Feb. 8, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its fourth-quarter and full-year 2017 financial results after the close of the U.S. financial markets on Feb. 22. Following the release, company management will host a webcast and conference call at 5 p.m. Eastern time to discuss financial results and business progress.
MADISON, Wis., Feb. 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference during February and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coca-Cola ...
President and CEO of Exact Sciences Corp (NASDAQ:EXAS) Kevin T Conroy sold 110,439 shares of EXAS on 01/23/2018 at an average price of $50.49 a share.
NEW YORK , NY / ACCESSWIRE / January 24, 2018 / The S&P 500 Index and Nasdaq rose to new records Tuesday on upbeat earnings. The S&P 500 Index gained 0.22 percent to close at a record 2,839.13, while the ...
In this analysis, my focus will be on developing a perspective on Exact Sciences Corporation’s (NASDAQ:EXAS) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...
IN THE NEWS Five weed stocks to watch in 2018: Link Just as the global cryptocurrency market is hitting its biggest rough patch in months, two new ETFs based on blockchain technology are making their market ...
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 16. Over the last one-month, outflows of investor capital in ETFs holding EXAS totaled $1.34 billion.
EXACT Sciences Corporation (NASDAQ: EXAS ) stock tumbled nearly 10 percent Wednesday after the American Society of Clinical Oncology announced results from a new study on liquid biopsy tests for colorectal ...
Shares of Exact Sciences (EXAS) are down more than 10% on Wednesday, hurt by news of a potential competitor to its test for colorectal cancer. The American Society for Clinical Oncology (ASCO) announced that a liquid biopsy shows promise at detecting early stage colorectal cancer, and more detail is expected at the association's Gastrointestinal Cancers Symposium this Saturday. In addition, the data is from a single center study in Taiwan, Myers notes, which calls for follow up research, rather than a big selloff in Exact Sciences. Exact Sciences is down 10.2% to $47.57 this afternoon.
NEW YORK, NY / ACCESSWIRE / January 15, 2018 / Concert Pharmaceuticals shares crumbled on Friday after it was revealed that the company's CTP-543 treatment could infringe on Incyte's patent and after CEO ...
Several companies made headlines after hours, including Advanced Micro Devices, Inc. (NASDAQ:AMD), EXACT Sciences Corporation (NASDAQ:EXAS) and International Business Machines Corp. (NYSE:IBM). Advanced Micro Devices admitted that its chips may have a vulnerability. About a week ago, the company said that there was almost no risk of AMD chips being affected by a variant of the Spectre vulnerability.
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 1.0% convertible senior notes due 2025 (the "Notes"), and upsized the offering from $500 million to $600 million aggregate principal amount, pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90 million aggregate principal amount of Notes. The closing of the offering is expected to occur on January 17, 2018 and is subject to customary closing conditions.
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) today announced an underwritten public offering of $500 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $75 million aggregate principal amount of Notes. The Company intends to use the net proceeds of this offering for general corporate and working capital purposes. The Notes will be convertible into cash, shares of the Company's common stock (plus, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / It was a day of losses for ACADIA on Monday, closing the day down a little over 6% at $27.11. There was no major news from the company whose stock was trading ...